TY - JOUR
T1 - Clinical use of lithium salts
T2 - guide for users and prescribers
AU - for the International Group for Studies of Lithium (IGSLi)
AU - Tondo, Leonardo
AU - Alda, Martin
AU - Bauer, Michael
AU - Bergink, Veerle
AU - Grof, Paul
AU - Hajek, Tomas
AU - Lewitka, Ute
AU - Licht, Rasmus W.
AU - Manchia, Mirko
AU - Müller-Oerlinghausen, Bruno
AU - Nielsen, René E.
AU - Selo, Marylou
AU - Simhandl, Christian
AU - Baldessarini, Ross J.
N1 - Funding Information:
Supported by grants from the Bruce J Anderson Foundation and the McLean Private Donors Psychiatric Research Fund (to RJB). VB has received grants by the Blavatnik Women’s Health institute. RWL has received research grants from Glaxo Smith Kline, honoraria for lecturing from Pfizer, Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Otsuka, Servier and honoraria from advisory board activity from Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag and Sunovion. LT has received honoraria from advisory board for Angelini. No other authors or immediate family members have financial relationships with commercial entities that might appear to represent potential conflicts of interest with the information presented. The remaining authors declare that they have no competing interests.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.
AB - Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.
KW - Bipolar disorder
KW - Blood testing
KW - Dosing
KW - Lithium
KW - Side-effects
UR - http://www.scopus.com/inward/record.url?scp=85069477845&partnerID=8YFLogxK
U2 - 10.1186/s40345-019-0151-2
DO - 10.1186/s40345-019-0151-2
M3 - Review article
AN - SCOPUS:85069477845
SN - 2194-7511
VL - 7
JO - International Journal of Bipolar Disorders
JF - International Journal of Bipolar Disorders
IS - 1
M1 - 16
ER -